Skip Navigation



American Journal of Epidemiology Advance Access published online on July 13, 2005
American Journal of Epidemiology, doi:10.1093/aje/kwi203
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
162/4/318    most recent
kwi203v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shannon, J.
Right arrow Articles by Farris, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shannon, J.
Right arrow Articles by Farris, P. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Copyright © 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved
Received December 3, 2004
Accepted March 31, 2005

ORIGINAL CONTRIBUTIONS

Statins and Prostate Cancer Risk: A Case-Control Study

Jackilen Shannon 1*, Selome Tewoderos 2, Mark Garzotto 1, Tomasz M. Beer 2, Rhianna Derenick 2, Amy Palma 1, and Paige E. Farris 1

1 Oregon Health & Sciences University, Portland, OR; Portland Veterans Affairs Medical Center, Portland, OR
2 Oregon Health & Sciences University, Portland, OR

* To whom correspondence should be addressed.
Jackilen Shannon, E-mail: shannoja{at}ohsu.edu


  Abstract

Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of ≥7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.

Keywords: case-control studies; cholesterol; hydroxymethylglutaryl-CoA reductase inhibitors; mevalonic acid; prostate-specific antigen; prostatic neoplasms; veterans.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 VASC ENDOVASCULAR SURGHome page
R. H. Samson
The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366.
[Abstract] [PDF]

Home page
 Am J EpidemiolHome page
I. Agalliu, C. A. Salinas, P. D. Hansten, E. A. Ostrander, and J. L. Stanford
Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study
Am. J. Epidemiol., August 1, 2008; 168(3): 250 - 260.
[Abstract] [Full Text] [PDF]

Home page
 American Journal of Men's HealthHome page
J. Jayachandran and S. J. Freedland
Prevention of Prostate Cancer: What We Know and Where We Are Going
American Journal of Men's Health, June 1, 2008; 2(2): 178 - 189.
[Abstract] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Hoque, H. Chen, and X.-c. Xu
Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 88 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. J. Murtola, T. L.J. Tammela, J. Lahtela, and A. Auvinen
Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2226 - 2232.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al.
Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. J. Jacobs, C. Rodriguez, E. B. Bain, Y. Wang, M. J. Thun, and E. E. Calle
Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2213 - 2217.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. A. Platz
Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2175 - 2180.
[Full Text] [PDF]

Home page
 NEJMHome page
I. Ford, H. Murray, C. J. Packard, J. Shepherd, P. W. Macfarlane, S. M. Cobbe, and the West of Scotland Coronary Prevention Study Gro
Long-Term Follow-up of the West of Scotland Coronary Prevention Study
N. Engl. J. Med., October 11, 2007; 357(15): 1477 - 1486.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zheng, X.-X. Cui, G. E. Avila, M.-T. Huang, Y. Liu, J. Patel, A. N. T. Kong, R. Paulino, W. J. Shih, Y. Lin, et al.
Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice
Clin. Cancer Res., September 15, 2007; 13(18): 5480 - 5487.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
V. Khurana, H. R. Bejjanki, G. Caldito, and M. W. Owens
Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans
Chest, May 1, 2007; 131(5): 1282 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Setoguchi, R. J. Glynn, J. Avorn, H. Mogun, and S. Schneeweiss
Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly
Circulation, January 2, 2007; 115(1): 27 - 33.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. A. Platz, M. F. Leitzmann, K. Visvanathan, E. B. Rimm, M. J. Stampfer, W. C. Willett, and E. Giovannucci
Statin Drugs and Risk of Advanced Prostate Cancer
J Natl Cancer Inst, December 20, 2006; 98(24): 1819 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
O. Landgren, Y. Zhang, S. H. Zahm, P. Inskip, T. Zheng, and D. Baris
Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2342 - 2347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras
Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
J. Clin. Oncol., October 20, 2006; 24(30): 4808 - 4817.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Z. Gong, M. L. Neuhouser, P. J. Goodman, D. Albanes, C. Chi, A. W. Hsing, S. M. Lippman, E. A. Platz, M. N. Pollak, I. M. Thompson, et al.
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1977 - 1983.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Bravi, L. Scotti, C. Bosetti, R. Talamini, E. Negri, M. Montella, S. Franceschi, and C. La Vecchia
Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer
Ann. Onc., June 1, 2006; 17(6): 1014 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard
The Role of Statins in Cancer Therapy.
Oncologist, January 1, 2006; 11(3): 306 - 315.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.